Market cap
$2.6bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
The increase in revenue was largely driven by an increase in demand for our approved products, as well as timing of shipments. Results of Operations Comparison of the three and six months ended June 30, 2026 to the three and six months ended June 30, 2025: Revenue (dollars in millions) Our product sales increased for the three and six months ended June 30, 2026, as compared to the same periods in 2025. The increase was largely due to increased product sales for Crysvita, primarily in LATAM territories due to an increase in the number of patients as well as timing of shipments, and the continued expansion of Evkeeza in territories outside of the United States. …Ultragenyx Pharmaceutical Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05